NASD · Healthcare · Diagnostics & Research · USA
Castle Biosciences Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.
Castle Biosciences is a molecular diagnostics company offering gene expression profile tests to aid clinicians in diagnosing and treating dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company generates revenue primarily through reimbursement from government and commercial payors in the United States.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Castle Biosciences Inc stock.
Overvalued: intrinsic value $8.22 per share, market price $32.98, margin of safety -301.1% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $8.22; the price of $32.98 is 301% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
16 more in this industry show a wider margin of safety.
CSTL is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $8.22; the price of $32.98 is 301% above that value.
$8.22 per share (as of the 2026-11-17 close), against a market price of $32.98. That is a margin of safety of -301.1%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.